1.50 / AMA PRA Category 1 Credit(s)TM 1.50 / CE for Nurses
Jointly provided by CancerNet, LLC, and Amedco
Supported by Novartis Pharmaceuticals Corporation
This webcast is intended to improve care of patients with chronic myeloid leukemia (CML) by accelerating adoption of new guidelines and evidence-based practice change. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This Internet CME activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.
This webcast is designed to meet the educational needs of hematologists/oncologists, physician assistants, nurse practitioners, registered nurses, pharmacists and fellows in training involved in the diagnosis and treatment of patients with CML.
As a result of participating in the activity, learners should be better able to:
Identify response assessment and management of tyrosine kinase inhibitor resistance in the treatment of CML
Cite the time-based response milestones and monitoring in patients with CML
Understand the concept of treatment-free remission after discontinuing nilotinib or dasatinib in patients with chronic-phase philadelphia chromosome–positive CML
Conflict Of Interest Disclosure Policy
It is the policy of the Amedco to ensure activity content is balanced, independent, objective and based on scientific bestevidence. All persons in a position to control content (i.e., course director, planning committee member and speaker) were required to disclose any relevant financial relationship with a commercial entity relative to the content of his/her presentation.
Jorge Cortes, MD Professor and Chair Department of Leukemia Division of Cancer Medicine The University of Texas M D Anderson Cancer Center Houston, TX
Dr. Cortes discloses that he is a consultant of BMS, Novaratis, Pfizer, Biopath, and Jazz and received research support from BMS, Novartis, Pfizer, Biopath, Jazz, Darichi, and Astellas.
Michael Deininger, MD, PhD Chief of the Division of Hematology University of Utah School of Medicine Salt Lake City, UT
Dr. Deininger discloses that he is a consultant of Incyte, Novartis Pharma, Pfizer, Inc.; is on the advisory boards of Ariad, Blueprint, Galena Biophartma, Incyte, Novartis Pharma, and Pfizer, Inc.; and received research funding from Novartis Pharma, and Pfizer, Inc.
Michael Mauro, MD Leader, Myeloproliferative Neoplasms Program Attending Physician, Leukemia Service Member, Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell Medical College New York, NY
Dr. Mauro discloses that he is a consultant of Novartis, BMS, Pfizer, and Takeda and received research funding from Novartis and Takeda.
Planners' and Managers' Disclosures
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE webcast:
Jorge Cortes, MD, is a consultant of BMS, Novaratis, Pfizer, Biopath, and Jazz and received research support from BMS, Novartis, Pfizer, Biopath, Jazz, Darichi, and Astellas.
Kamatham A. Naidu, PhD (CancerNet), has no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Amedco and CancerNet, LLC. Amedco is accredited by the ACCME to provide continuing medical education for physicians.
Amedco designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)TM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE for Nurses
Amedco is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This course is co-provided by Amedco and CancerNet, LLC.
This course provides a maximum of 1.50 contact hours.
Disclosure of Unlabeled Use
It is the policy of the Amedco to inform each speaker of his/her responsibility to disclose to the attendees when products or procedures discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved) and of any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.
Each speaker reported he/she will notify the audience if/when discussion includes off-label, unlabeled, experimental, and/or investigational (not FDA approved) information or limited use references within the content of his/her presentation.
The information provided at this educational initiative is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
Non-Endorsement of Products
The Amedco do not imply either real or implied endorsement of any product, service, or company referred to in this educational activity.
There are no fees for participating and receiving CE credit for this webcast. During the period December 20, 2017 through December 20, 2018, participants must read all the material and study the educational webcast.
This webcast includes text, graphics, and may include multimedia features.
To obtain credit, a score of 80% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
If you have any questions relating to the accreditation of this activity, please contact the CE Provider at email@example.com.
Amedco observes privacy and confidentiality of CE information and personal information of CE participants. Third parties receive only aggregated data about CE activities that are relevant to their interests and/or the activities they support.